19th Ave New York, NY 95822, USA

Tumor Immunology & Immunotherapy Group

Tumor Immunology & Immunotherapy Group VHIO

Immunotherapies against cancer exploit the immune system to more effectively attack disease. Clinical studies have shown that immune checkpoint inhibitors and T-cell-based therapies can mediate tumor regression in cancer patients with metastatic disease. Thus, in addition to surgery, radiation therapy and chemotherapy, immunotherapy is increasingly representing the fourth pillar of anti-cancer therapy across various tumor types.

Despite encouraging antitumor responses, currently only a fraction of patients treated with immune-based therapies respond, and some unfortunately report autoimmune- related adverse events. There is therefore a critical need to develop and personalize these promising treatments.

To do so, and thanks to the support received from the BBVA Foundation’s Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI) at VHIO, we study mechanisms of response, toxicity and resistance to cancer immunotherapeutics in patients at the Vall d’Hebron University Hospital (HUVH). We aim to identify biomarkers of response in liquid biopsies.

One correlative biomarker described to-date is mutation burden. Tumor-specific somatic mutations are optimal targets for cancer immunotherapy and render tumors immunogenic; some of these can bind to the patients’ human leukocyte antigen (HLA) molecules and elicit T-cell responses.

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor responses to develop more effective, powerful, and personalized immunotherapies against cancer.

We have recently filed an investigational new drug (IND) application to the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS – Spanish Regulatory Agency), in February 2021 that will enable us to treat patients with metastatic epithelial or immunotherapy refractory cancers with neoantigen-reactive TILs using this personalized approach. By enriching for neoantigen-reactive lymphocytes, we hope to enhance the efficacy of TIL therapy in epithelial cancers.

Alena Gros
Alena Gros
Group Leader
  • Characterize the personalized anti-tumor T-cell response in cancer patients.
  • Mine the personalized repertoire of tumor-reactive lymphocytes for potential biomarkers of response to cancer immunotherapy.
  • Investigate novel strategies to more swiftly identify tumor-reactive lymphocytes as well as the target antigens driving this response.
  • Study the tumor cell intrinsic mechanisms of resistance to T cell mediated cytotoxicity
  • Develop personalized T-cell-based cancer immunotherapies for patients with solid tumors.

Figure: Personalized approach to identify tumor and neoantigen- specific TILs. a) We sequence normal and tumor DNA to identify all the non-synonymous mutations. b) In parallel we attempt to generate a tumor cell line. When generated, we isolate the peptide-MHCI complexes and we identify the peptides presented by MHCI by the tumor cell line by Mass spectrometry. c) Finally, we screen the TILs expanded from the tumor for recognition of the candidate neoantigen peptides identified in a) or elluted from MHCI in b).

Tumor Immunology & Immunotherapy Group VHIO
Group Leader
Alena Gros
Post-Doctoral Fellows
Jara Palomero
Pierre Levy
Graduate Students
Judit Díaz
Andrea García
Maria Lozano
Anna Yuste
Technicians
Albert Marín
Immaculada Creus
Lab Manager
Noelia Alcazar
Computational Technician
Jonatan González
  • Gartner JJ, Parkhurst MR, Gros A, Tran E, Jafferji MS, Copeland A, Hanada KI, Zacharakis N, Lalani A, Krishna S, Sachs A, Prickett TD, Li YF, Florentin M, Kivitz S, Chatmon SC, Rosenberg SA, Robbins PF. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. Nat Cancer. 2021 May;2(5):563-574.
  • Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, Fajardo CA, Gros A, Klein C, Arribas J. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021 Feb 23;12(1):1237.
  • Kast F, Klein C, Umaña P, Gros A, Gasser S. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. Oncoimmunology. 2021 Jan 7;10(1):1869389.
  • Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, Fajardo CA, Gros A, Klein C, Arribas J. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021 Feb 23;12(1):1237. doi: 10.1038/s41467-021-21445-4. PMID: 33623012; PMCID: PMC7902842.
  • Kast F, Klein C, Umaña P, Gros A, Gasser S. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. Oncoimmunology. 2021 Jan 7;10(1):1869389. doi: 10.1080/2162402X.2020.1869389. PMID: 33520408; PMCID: PMC7808433.
  • Lozano-Rabella M, Gros A. TCR Repertoire Changes during TIL Expansion: Clonal Selection or Drifting? Clin Cancer Res. 2020 Aug 15;26(16):4177-4179
  • Gros A, Tran E, Parkhurst MR, Ilyas S, Pasetto A, Groh EM, Robbins PF, Yossef R, Garcia-Garijo A, Fajardo CA, Prickett TD, Jia L, Gartner JJ, Ray S, Ngo L, Wunderllich JR, Yang JC, Rosenberg SA. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. J Clin Invest. 2019 Nov 1;129(11):4992-5004.
  • Garcia-Garijo A, Fajardo CA, Gros A. Determinants for Neoantigen Identification. Front Immunol. 2019 Jun 24;10:1392.
  • Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, Rosenberg SA. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight. 2018 Oct 4;3(19). pii: 122467.
  • R. Eil, S.K. Vodnala, D. Clever, C.A. Klebanoff, M.Sukumar, J.H. Pan, D.C. Palmer, A. Gros, T.N. Yamamoto, S.J. Patel, G.C. Guittard, Z. Yu, V. Carbonaro, K. Okkenhaug, D.S. Schrump, W.M. Linehan, R. Roychoudhuri, N.P. Restifo. Ionic immune suppression within the tumour microenvironment limits T cell effector function, Nature, 14 (2016) 539-543.
  • A. Pasetto, A. Gros, P.F. Robbins, D.C. Deniger, R.D. Prickett, R. Matus-Nicodemos, D.C. Douek, B. Howie, H. Robins, M.R. Parkhurst, J. Gartner, K. Trebska-McGowan, J.S. Crystal, S.A. Rosenberg.Tumor- and Neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor.Cancer Immunol 2 (2016) 734-743.
  • T.D. Prickett, J.S. Crystal, C.J. Cohen, A. Pasetto, M.R. Parkhurst, J.J. Gartner, X. Yao, R. Wang, A. Gros, Y.F. Li, M. El-Gamil, K. Trebska-McGowan, S.A. Rosenberg, P.F. Robbins, Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens, Cancer Immunol Res, (2016).
  • C.A. Klebanoff, C.D. Scott, A.J. Leonardi, T.N. Yamamoto, A.C. Cruz, C. Ouyang, M. Ramaswamy, R. Roychoudhuri, Y. Ji, R.L. Eil, M. Sukumar, J.G. Crompton, D.C. Palmer, Z.A. Borman, D. Clever, S.K. Thomas, S. Patel, Z. Yu, P. Muranski, H. Liu, E. Wang, F.M. Marincola, A. Gros, L. Gattinoni, S.A. Rosenberg, R.M. Siegel, N.P. Restifo, Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy, J Clin Invest, 126 (2016) 318-334.
  • A. Gros, M.R. Parkhurst, E. Tran, A. Pasetto, P.F. Robbins, S. Ilyas, T.D. Prickett, J.J. Gartner, J.S. Crystal, I.M. Roberts, K. Trebska-McGowan, J.R. Wunderlich, J.C. Yang, S.A. Rosenberg, Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients, Nat Med, 22 (2016) 433-438.
  • E. Tran, M. Ahmadzadeh, Y.C. Lu, A. Gros, S. Turcotte, P.F. Robbins, J.J. Gartner, Z. Zheng, Y.F. Li, S. Ray, J.R. Wunderlich, R.P. Somerville, S.A. Rosenberg, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350 (2015) 1387-1390.
  • L.M. Draper, M.L. Kwong, A. Gros, S. Stevanovic, E. Tran, S. Kerkar, M. Raffeld, S.A. Rosenberg, C.S. Hinrichs, Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6, Clin Cancer Res, 21 (2015) 4431-4439.
  • J.G. Crompton, M. Sukumar, R. Roychoudhuri, D. Clever, A. Gros, R.L. Eil, E. Tran, K. Hanada, Z. Yu, D.C. Palmer, S.P. Kerkar, R.D. Michalek, T. Upham, A. Leonardi, N. Acquavella, E. Wang, F.M. Marincola, L. Gattinoni, P. Muranski, M.S. Sundrud, C.A. Klebanoff, S.A. Rosenberg, D.T. Fearon, N.P. Restifo, Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics, Cancer Res, 75 (2015) 296-305.
  • N. Acquavella, D. Clever, Z. Yu, M. Roelke-Parker, D.C. Palmer, L. Xi, H. Pflicke, Y. Ji, A. Gros, K. Hanada, I.S. Goldlust, G.U. Mehta, C.A. Klebanoff, J.G. Crompton, M. Sukumar, J.J. Morrow, Z. Franco, L. Gattinoni, H. Liu, E. Wang, F. Marincola, D.F. Stroncek, C.C. Lee, M. Raffeld, M.W. Bosenberg, R. Roychoudhuri, N.P. Restifo, Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest, Cancer Immunol Res, 3 (2015) 37-47.
  • S. Turcotte, A. Gros, E. Tran, C.C. Lee, J.R. Wunderlich, P.F. Robbins, S.A. Rosenberg, Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy, Clin Cancer Res, 20 (2014) 331-343.
  • E. Tran, S. Turcotte, A. Gros, P.F. Robbins, Y.C. Lu, M.E. Dudley, J.R. Wunderlich, R.P. Somerville, K. Hogan, C.S. Hinrichs, M.R. Parkhurst, J.C. Yang, S.A. Rosenberg, Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344 (2014) 641-645.
  • A. Gros, P.F. Robbins, X. Yao, Y.F. Li, S. Turcotte, E. Tran, J.R. Wunderlich, A. Mixon, S. Farid, M.E. Dudley, K. Hanada, J.R. Almeida, S. Darko, D.C. Douek, J.C. Yang, S.A. Rosenberg, PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors, J Clin Invest, 124 (2014) 2246-2259.
  • S. Turcotte, A. Gros, K. Hogan, E. Tran, C.S. Hinrichs, J.R. Wunderlich, M.E. Dudley, S.A. Rosenberg, Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy, J Immunol, 191 (2013) 2217-2225.
  • R.A. Morgan, N. Chinnasamy, D. Abate-Daga, A. Gros, P.F. Robbins, Z. Zheng, M.E. Dudley, S.A. Feldman, J.C. Yang, R.M. Sherry, G.Q. Phan, M.S. Hughes, U.S. Kammula, A.D. Miller, C.J. Hessman, A.A. Stewart, N.P. Restifo, M.M. Quezado, M. Alimchandani, A.Z. Rosenberg, A. Nath, T. Wang, B. Bielekova, S.C. Wuest, N. Akula, F.J. McMahon, S. Wilde, B. Mosetter, D.J. Schendel, C.M. Laurencot, S.A. Rosenberg, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J Immunother, 36 (2013) 133-151.
  • C. Puig-Saus, A. Gros, R. Alemany, M. Cascallo, Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers, Mol Ther, 20 (2012) 54-62.
  • S. Guedan, D. Grases, J.J. Rojas, A. Gros, F. Vilardell, R. Vile, E. Mercade, M. Cascallo, R. Alemany, GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution, Gene Ther, 19 (2012) 1048-1057.
  • A. Gros, S. Turcotte, J.R. Wunderlich, M. Ahmadzadeh, M.E. Dudley, S.A. Rosenberg, Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma, Clin Cancer Res, 18 (2012) 5212-5223.
  • M. Gimenez-Alejandre, A. Gros, R. Alemany, Construction of capsid-modified adenoviruses by recombination in yeast and purification by iodixanol-gradient, Methods Mol Biol, 797 (2012) 21-34.
  • L. Coughlan, S. Vallath, A. Gros, M. Gimenez-Alejandre, N. Van Rooijen, G.J. Thomas, A.H. Baker, M. Cascallo, R. Alemany, I.R. Hart, Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5, Hum Gene Ther, 23 (2012) 960-979.
  • S. Guedan, J.J. Rojas, A. Gros, E. Mercade, M. Cascallo, R. Alemany, Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth, Mol Ther, 18 (2010) 1275-1283.
  • A. Gros, C. Puig, S. Guedan, J.J. Rojas, R. Alemany, M. Cascallo, Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses, Mol Ther, 18 (2010) 903-911.
  • 22.- J.J. Rojas, M. Cascallo, S. Guedan, A. Gros, J. Martinez-Quintanilla, A. Hemminki, R. Alemany, A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses, Gene Ther, 16 (2009) 1441-1451.
  • J. Martinez-Quintanilla, M. Cascallo, A. Gros, C. Fillat, R. Alemany, Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy, Mol Cancer Ther, 8 (2009) 3098-3107.
  • M. Huch, A. Gros, A. Jose, J.R. Gonzalez, R. Alemany, C. Fillat, Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models, Neoplasia, 11 (2009) 518-528, 514 p following 528.
  • N. Bayo-Puxan, M. Gimenez-Alejandre, S. Lavilla-Alonso, A. Gros, M. Cascallo, A. Hemminki, R. Alemany, Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting, Hum Gene Ther, 20 (2009) 1214-1221.
  • S. Guedan, A. Gros, M. Cascallo, R. Vile, E. Mercade, R. Alemany, Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication, Gene Ther, 15 (2008) 1240-1245.
  • A. Gros, J. Martinez-Quintanilla, C. Puig, S. Guedan, D.G. Mollevi, R. Alemany, M. Cascallo, Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency, Cancer Res, 68 (2008) 8928-8937.
  • M. Cascallo, A. Gros, N. Bayo, T. Serrano, G. Capella, R. Alemany, Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses, Hum Gene Ther, 17 (2006) 929-940.
  • N. Bayo-Puxan, M. Cascallo, A. Gros, M. Huch, C. Fillat, R. Alemany, Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting, J Gen Virol, 87 (2006) 2487-2495.
  1. Grantor: Miguel Servet (Type 2). Title: Characterization of neoantigen-specific T cells and identification of predictive biomarkers of response in patients with MSI and MSI-like CRC treated with anti-PDL1.
  2. Grantor: Instituto de Salud Carlos III (ISCIII)Title: Terapia celular de próxima generación con TIL específicos de neoantígenos para pacientes con tumores resistentes a inhibidores de puntos de control inmunitario.
  3. Grantor: Fundación Fero (Beca Fero). Title: Non-invasive personalized T-cell therapies targeting recurrent hot spot driver mutations in cancer.
  4. Grantor: Fundación BBVA. Alena Gros is a member of the BBVA Foundation’s Immunotherapy & Immunology Program (CAIMI) at VHIO.
  5. Grantor: La Marató de TV3. Title: Personalized Immunotherapy for Endometrial Cancer.
  6. Grantor: La Caixa Health Research. Title: Development of enabling technologies for T-cell immunotherapy of solid tumors.
  7. Grantor: Ministerio de Ciencia e Innovación. Title: Mining the molecular determinants of the personalized T-cell response in cancer patients to develop more effective immunotherapies.